M.B. Assié

Levomilnacipran (F2695), a norepinephrine-preferring SNRI: Profile in vitro and in models of depression and anxiety

Agnès L. Auclair, J.-C. Martel, M.B. Assié et al. · Neuropharmacology · 2013 · 259 citations · Full text

Psychotropic Medication, Psychopharmacology, Pharmacotherapy +17

Large-amplitude 5-HT1A receptor activation: a new mechanism of profound, central analgesia

Françis C. Colpaert, J.P. Tarayre, Wouter Koek et al. · Neuropharmacology · 2002 · 136 citations

Molecular Pharmacology, Pain Syndrome, Health Sciences +14

Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release

Cristina Cosi, Elisabeth Carilla-Durand, M.B. Assié et al. · European Journal of Pharmacology · 2006 · 88 citations

Psychiatry, Functional Selectivity, Medicine +9

F 11440, a Potent, Selective, High Efficacy 5-HT1AReceptor Agonist with Marked Anxiolytic and Antidepressant Potential

Wouter Koek, Jean‐François Patoiseau, M.B. Assié et al. · Journal of Pharmacology and Experimental Therapeutics · 1998 · 63 citations

Effects of prolonged administration of milnacipran, a new antidepressant, on receptors and monoamine uptake in the brain of the rat

M.B. Assié, Marie Charvéron, Christiane Palmier et al. · Neuropharmacology · 1992 · 44 citations

Psychoactive Drug, Psychiatry, New Antidepressant +11